AEON Biopharma Revenue and Competitors
Estimated Revenue & Valuation
- AEON Biopharma's estimated annual revenue is currently $2.2M per year.
- AEON Biopharma's estimated revenue per employee is $201,000
Employee Data
- AEON Biopharma has 11 Employees.
- AEON Biopharma grew their employee count by -27% last year.
AEON Biopharma's People
Name | Title | Email/Phone |
---|---|---|
1 | President and CEO | Reveal Email/Phone |
2 | Office Manager | Reveal Email/Phone |
AEON Biopharma Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $102.7M | 511 | 25% | N/A | N/A |
#2 | $0.4M | 2 | 0% | N/A | N/A |
#3 | $38.6M | 192 | 3% | N/A | N/A |
#4 | $35M | 127 | 2% | $62.5M | N/A |
#5 | $36.6M | 182 | 18% | N/A | N/A |
#6 | $131.9M | 656 | -3% | N/A | N/A |
#7 | $133.5M | 664 | N/A | N/A | N/A |
#8 | $72.8M | 362 | -4% | N/A | N/A |
#9 | $551.9M | 1716 | -2% | N/A | N/A |
#10 | $11.7M | 58 | 12% | N/A | N/A |
What Is AEON Biopharma?
AEON Biopharma is a biopharmaceutical company focused on developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions. The company is dedicated to innovation in the rapidly expanding therapeutic botulinum toxin market. This therapeutic-only focus will allow AEON Biopharma to advance safe and effective treatment options to patients, while delivering differentiated economics to payors and physicians. The company continues to evaluate additional therapeutic indications for development based on a comprehensive product assessment process designed to identify those indications where it believes ABP-450 can attain clinical, regulatory and commercial success.
keywords:N/AN/A
Total Funding
11
Number of Employees
$2.2M
Revenue (est)
-27%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1M | 11 | 0% | N/A |
#2 | $0.3M | 11 | 0% | $110M |
#3 | $0.9M | 11 | N/A | N/A |
#4 | $1.1M | 11 | N/A | N/A |
#5 | $1M | 11 | N/A | N/A |